<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994318</url>
  </required_header>
  <id_info>
    <org_study_id>FER-CKD-01</org_study_id>
    <nct_id>NCT00994318</nct_id>
  </id_info>
  <brief_title>Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)</brief_title>
  <acronym>FIND-CKD</acronym>
  <official_title>An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject High and Low Dosage Regimens) Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vifor Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using
      targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic
      kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After an initial screening period of up to 4 weeks, eligible subjects were randomised (1:1:2)
      to 1 of the following 3 treatment arms for a period of 52 weeks.

        1. FCM regimen (maximum single intravenous doses of 1,000 mg of iron) targeting a ferritin
           level of 400-600 mcg/L.

        2. FCM regimen (maximum single intravenous doses of 200 mg of iron) targeting a ferritin
           level of 100-200 mcg/L.

        3. Daily oral iron with 200 mg iron/day (100 mg twice daily)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kaplan-Meier Survival Analysis for Time to Other Anemia Therapy or Hb Trigger</measure>
    <time_frame>Up to 1 year after baseline</time_frame>
    <description>Endpoint reported number of participants with/without events and was reached:
First time of initiation of additional or alternative anaemia management,
First time the subject reached the Hb trigger.
3 primary comparisons using a hierarchical step-down procedure on the log-rank test to preserve an alpha level of 0.05, performed in the following order:
FCM (high ferritin target) compared with oral iron.
FCM (high ferritin target) compared with FCM (low ferritin target).
FCM (low ferritin target) compared with oral iron.
Sensitivity analyses of the primary endpoint were performed using the following alternative definitions of time to initiation of additional or alternative anaemia management:
Without taking into account the Hb trigger.
Taking into account the Hb trigger based on local laboratory data, instead of central laboratory data.
Taking into account the Hb trigger based on subjects with a complete set of Hb values from the central laboratory.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">626</enrollment>
  <condition>Iron Deficiency Anaemia</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>FCM (high ferritin target)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FCM (low ferritin target)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferrous sulphate 100 mg iron twice daily, continuous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FCM (Ferric carboxymaltose) high ferritin target</intervention_name>
    <arm_group_label>FCM (high ferritin target)</arm_group_label>
    <other_name>Ferinject</other_name>
    <other_name>Injectafer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FCM (Ferric carboxymaltose) low ferritin target</intervention_name>
    <arm_group_label>FCM (low ferritin target)</arm_group_label>
    <other_name>Ferinject</other_name>
    <other_name>Injectafer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Iron (Ferrous sulphate)</intervention_name>
    <arm_group_label>Oral Iron</arm_group_label>
    <other_name>Ferrous sulphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years of age.

          2. NDD-CKD subjects with an estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73
             m2 using modification of diet in renal disease 4 (MDRD-4) calculation.

          3. NDD-CKD subjects with an eGFR loss ≤12 mL/min/1.73 m2/year and a predicted eGFR of ≥15
             mL/min/1.73 m2 in 12 months.

          4. Any single Hb between 9 and 11 g/dL within 4 weeks of randomisation. A value taken as
             part of routine medical care was used.

          5. Any single serum ferritin &lt;100 mcg/L or &lt;200 mcg/L with TSAT &lt;20% within 4 weeks of
             randomisation. Measurements taken as part of routine medical care were used.

          6. ESA naïve; no exposure to ESA in last 4 months prior to randomisation.

          7. Females of childbearing potential must have had a negative pregnancy test, using any
             medically acceptable assessment, prior to randomisation.

          8. Before any study specific procedure, the appropriate written informed consent must
             have been obtained.

        Exclusion Criteria:

          1. History of acquired iron overload.

          2. Known hypersensitivity reaction to any component of ferrous sulphate or FCM. Subjects
             with hypersensitivity to other forms of iron were permitted to participate.

          3. Documented history of discontinuing oral iron products due to significant
             gastrointestinal (GI) distress.

          4. Screening TSAT &gt;40%.

          5. Known active infection, C-reactive protein &gt;20 mg/L, clinically significant overt
             bleeding, active malignancy (i.e., clinical evidence of current malignancy or not in
             stable remission for at least 5 years since completion of last treatment with
             exception of basal cell or squamous cell carcinoma of the skin, and cervical
             intraepithelial neoplasia).

          6. History of chronic alcohol abuse (alcohol consumption &gt;40 g/day).

          7. Chronic liver disease and/or screening alanine transaminase or aspartate transaminase
             above 3 times the upper limit of the normal range.

          8. Active human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome or active
             hepatitis B or C virus infection.

          9. Anaemia due to reasons other than iron deficiency (e.g., haemoglobinopathy). Subjects
             with treated Vitamin B12 or folic acid deficiency were permitted.

         10. IV iron and/or blood transfusion in previous 30 days prior to screening (or during the
             screening period).

         11. Oral iron therapy at doses &gt;100 mg/day dosing must have been discontinued at least 1
             week prior to randomisation. If subject had received this therapy for &gt;3 months (at
             doses &gt;100 mg/day) then subject was not eligible. Ongoing use of multivitamins
             containing iron was permitted.

         12. Immunosuppressive therapy that may have led to anaemia (e.g., cyclophosphamide,
             azathioprine, or mycophenolate mofetil). Steroid therapy was permitted.

         13. Currently requiring renal dialysis.

         14. Anticipated dialysis or transplant during the study.

         15. Anticipated need for surgery that may have resulted in significant bleeding (&gt;100 mL).

         16. Currently suffering from chronic heart failure New York Heart Association Class IV.

         17. Poorly controlled hypertension (&gt;160 mmHg systolic pressure or &gt;100 mmHg diastolic
             pressure).

         18. Acute coronary syndrome or stroke within the 3 months prior to screening.

         19. Currently suffering from concomitant, severe psychiatric disorders or other conditions
             which, in the opinion of the Investigator, would have made participation unacceptable.

         20. Subject was not using adequate contraceptive precautions.

         21. Subject of childbearing potential was evidently pregnant (e.g., positive human
             chorionic gonadotropin test) or was breast feeding.

         22. Body weight &lt;35 kg.

         23. Subject currently was enrolled in or had not yet completed at least 30 days since
             ending other investigational device or drug studies, or subject was receiving other
             investigational agent(s).

         24. Subject would not be available for follow-up assessment.

         25. Subject had any kind of disorder that compromised the ability of the subject to give
             written informed consent and/or to comply with study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iain Macdougall</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trial Management Associates</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital - Renal Research</name>
      <address>
        <city>Gosford</city>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin IV</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHMS Baudour - Department of Nephrology and Dialysis</name>
      <address>
        <city>Baudour</city>
        <zip>7331</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice s poliklinikou v Novem Jicine, p.o. p.o. Interni oddeleni - nefrologie a dialyza</name>
      <address>
        <city>Novy Jicin</city>
        <zip>74101</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillebalt Frederica Sygehus Department of Nephrology</name>
      <address>
        <city>Frederica</city>
        <zip>7000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU grenoble - Service de Nephrologie</name>
      <address>
        <city>Grenoble Cedex</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kraatz</name>
      <address>
        <city>Demmin</city>
        <zip>17109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Arta - Nephrology Department</name>
      <address>
        <city>Arta</city>
        <zip>47100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Anzio-Nettuno ASL ROMA H U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Anzio</city>
        <zip>00042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum - Locatie Amersfoort Lichtenberg</name>
      <address>
        <city>Amersfoort</city>
        <zip>3816 CP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olav's Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miedzyleski Szpital Spec. Oddzial I Wewnetrzny I Nefrologii</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria - Nefrologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Nefrologie&quot;Dr Carol Davila&quot;</name>
      <address>
        <city>Bucuresti</city>
        <zip>010731</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla - Servicio de Nefrología</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>141</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova University Medical Faculty Balcali Hospital - Department of Nephrology</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <results_first_submitted>April 4, 2014</results_first_submitted>
  <results_first_submitted_qc>April 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2014</results_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ferinject Iron Deficiency Anaemia Chronic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FCM (High Ferritin Target)</title>
          <description>Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L</description>
        </group>
        <group group_id="P2">
          <title>FCM (Low Ferritin Target)</title>
          <description>Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L</description>
        </group>
        <group group_id="P3">
          <title>Oral Iron</title>
          <description>Ferrous sulphate 100 mg iron twice daily, continuous</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="317"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="67"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population is the Full Analysis Set (FAS); all subjects randomised to treatment, received at least 1 dose study drug or, per protocol, not treated due to ferritin &lt;100 mcg/L, and attended at least 1 post-baseline visit with at least 1 non-missing assessment. Overall 626 subjects were randomised, the FAS consists of 613 subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>FCM (High Ferritin Target</title>
          <description>Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L</description>
        </group>
        <group group_id="B2">
          <title>FCM (Low Ferritin Target)</title>
          <description>Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L</description>
        </group>
        <group group_id="B3">
          <title>Oral Iron</title>
          <description>Ferrous sulphate 100 mg iron twice daily, continuous</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="308"/>
            <count group_id="B4" value="613"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="216"/>
                    <measurement group_id="B4" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.46" spread="12.643"/>
                    <measurement group_id="B2" value="68.19" spread="13.264"/>
                    <measurement group_id="B3" value="69.31" spread="13.404"/>
                    <measurement group_id="B4" value="69.07" spread="13.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="291"/>
                    <measurement group_id="B4" value="584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Kaplan-Meier Survival Analysis for Time to Other Anemia Therapy or Hb Trigger</title>
        <description>Endpoint reported number of participants with/without events and was reached:
First time of initiation of additional or alternative anaemia management,
First time the subject reached the Hb trigger.
3 primary comparisons using a hierarchical step-down procedure on the log-rank test to preserve an alpha level of 0.05, performed in the following order:
FCM (high ferritin target) compared with oral iron.
FCM (high ferritin target) compared with FCM (low ferritin target).
FCM (low ferritin target) compared with oral iron.
Sensitivity analyses of the primary endpoint were performed using the following alternative definitions of time to initiation of additional or alternative anaemia management:
Without taking into account the Hb trigger.
Taking into account the Hb trigger based on local laboratory data, instead of central laboratory data.
Taking into account the Hb trigger based on subjects with a complete set of Hb values from the central laboratory.</description>
        <time_frame>Up to 1 year after baseline</time_frame>
        <population>The Full Analysis Set (FAS) was used for the primary endpoint analysis, which consisted of all subjects randomised to treatment, received at least 1 dose of study treatment or, according to the protocol, were not treated due to ferritin value &lt;100 mcg/L, and attended at least 1 post-baseline visit with at least 1 non-missing assessment available.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (High Ferritin Target)</title>
            <description>Ferric carboxymaltose (FCM) (Ferinject / Injectafer), targeting ferritin level of 400-600 mcg/L</description>
          </group>
          <group group_id="O2">
            <title>FCM (Low Ferritin Level)</title>
            <description>Ferric carboxymaltose (FCM) (Ferinject / Injectafer), targeting ferritin level of 100-200 mcg/L</description>
          </group>
          <group group_id="O3">
            <title>Oral Iron</title>
            <description>Ferrous sulphate 100 mg iron twice daily, continuous</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Survival Analysis for Time to Other Anemia Therapy or Hb Trigger</title>
          <description>Endpoint reported number of participants with/without events and was reached:
First time of initiation of additional or alternative anaemia management,
First time the subject reached the Hb trigger.
3 primary comparisons using a hierarchical step-down procedure on the log-rank test to preserve an alpha level of 0.05, performed in the following order:
FCM (high ferritin target) compared with oral iron.
FCM (high ferritin target) compared with FCM (low ferritin target).
FCM (low ferritin target) compared with oral iron.
Sensitivity analyses of the primary endpoint were performed using the following alternative definitions of time to initiation of additional or alternative anaemia management:
Without taking into account the Hb trigger.
Taking into account the Hb trigger based on local laboratory data, instead of central laboratory data.
Taking into account the Hb trigger based on subjects with a complete set of Hb values from the central laboratory.</description>
          <population>The Full Analysis Set (FAS) was used for the primary endpoint analysis, which consisted of all subjects randomised to treatment, received at least 1 dose of study treatment or, according to the protocol, were not treated due to ferritin value &lt;100 mcg/L, and attended at least 1 post-baseline visit with at least 1 non-missing assessment available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="7.65"/>
                    <measurement group_id="O2" value="49" spread="9.47" lower_limit="0.45" upper_limit="1.05"/>
                    <measurement group_id="O3" value="98" spread="7.71" lower_limit="0.44" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FCM (Ferinject / Injectafer) targeting high ferritin level (400 - 600 mcg/L) compared with Oral Iron (Ferrous sulphate 100 mg iron twice daily).
Three primary comparisons using a hierarchical step-down procedure on the log-rank test to preserve the overall alpha level of 0.05, performed in the following order:
FCM (high ferritin target) compared with oral iron.
FCM (high ferritin target) compared with FCM (low ferritin target).
FCM (low ferritin target) compared with oral iron.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FCM (Ferinject / Injectafer) targeting high ferritin level (400-600mcg/L) compared with FCM targeting low ferritin level (100 - 200 mcg/L).
Three primary comparisons using a hierarchical step-down procedure on the log-rank test to preserve the overall alpha level of 0.05, performed in the following order:
FCM (high ferritin target) compared with oral iron.
FCM (high ferritin target) compared with FCM (low ferritin target).
FCM (low ferritin target) compared with oral iron.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sensitivity analysis of the primary endpoint. Time to initiation of additional or alternative anaemia management without taking into account the Hb trigger.
FCM (Ferinject / Injectafer) targeting high ferritin level (400 - 600 mcg/L) compared with Oral Iron (Ferrous sulphate 100 mg iron twice daily).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sensitivity analysis of the primary endpoint. Time to initiation of additional or alternative anaemia management taking into account the Hb trigger based on local laboratory data, instead of central laboratory data.
FCM (Ferinject / Injectafer) targeting high ferritin level (400 - 600 mcg/L) compared with Oral Iron (Ferrous sulphate 100 mg iron twice daily).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sensitivity analysis of the primary endpoint. Time to initiation of additional or alternative anaemia management taking into account the Hb trigger based on subjects with a complete set of Hb values from central laboratory.
FCM (Ferinject / Injectafer) targeting high ferritin level (400 - 600 mcg/L) compared with Oral Iron (Ferrous sulphate 100 mg iron twice daily)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data was collected for 56 weeks after baseline.</time_frame>
      <desc>The Number of Patients at Risk is the Safety Set which consists of all randomised subjects who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>FCM (High Ferritin Target)</title>
          <description>Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L</description>
        </group>
        <group group_id="E2">
          <title>FCM (Low Ferritin Target)</title>
          <description>Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L</description>
        </group>
        <group group_id="E3">
          <title>Oral Iron</title>
          <description>Ferrous sulphate 100 mg iron twice daily, continuous</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Nephrogenic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hypertensive Heart Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Left Ventricular Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Sinus Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Entercolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pancreatic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia, Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Device Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hernia Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Infective Exacerbation of Chronic Obstructive Airways Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Infected Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Wound Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Wound Infection Staphlyococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cervical Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Ligament Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Perirenal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Renal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>International Normalised Ratio Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Fluid Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>B-Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Burkitt's Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Laryngeal Cancer Recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Lung Carcinoma Cell Type Unspecified Recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Multiple Myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Myelodysplastic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Neuroendocrine Carcinoma of the Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Small Cell Lung Cancer Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Thyroid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Orthostatic Intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Nephrotic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cystitis Glandularis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Renal Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Drug Eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="255" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators may not present or publish partial or complete study results individually. Any manuscript or abstract proposed by the Investigators must be reviewed and approved in writing by Vifor Pharma before submission for publication. Names of all Investigators participating in the study will be included in the publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Initially 1,016 subjects were planned, but due to slow enrollment only 626 were randomised which was sufficient to make the primary comparison between FCM targeting high ferritin level and oral iron.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>Vifor Pharma</organization>
      <phone>41 58 851 8222</phone>
      <email>medinfo@viforpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

